Papers by Dr. GA Fava, long-time critic of antidepressants

[Altostrata]

Psychother Psychosom. 2002 May-Jun;71(3):127-32.

Long-term treatment with antidepressant drugs: the spectacular achievements of propaganda.

Fava GA.

 

Long-Term Treatment with Antidepressant Drugs: The Spectacular Achievements of Propaganda

 

Editorial Psychother Psychosom 2002;71:127–132

 

Giovanni A.Fava

 

Affective Disorders Program, Department of Psychology, University of Bologna, Bologna, Italy;

Department of Psychiatry, State University of New York at Buffalo, Buffalo, N.Y., USA

 

In the medical field, the term ‘propaganda’ generally refers to open and direct pharmaceutical operations (e.g. advertisements, talks by sales representatives and presents). It also has, however, a more subtle and pervasive connotation, related to media control. Noam Chomsky has been instrumental in disclosing such a link. He dates the first modern example of media control from the occasion when Woodrow Wilson was elected President of the United States in 1916, right in the middle of World War I:

 

‘The population was extremely pacifistic and saw no

reason to become involved in a European war. The Wil-

son administration was actually committed to war and

had to do something about it. They established a govern-

ment propaganda commission, called the Creel Commis-

sion, which succeeded, within six months, in turning a

pacifist population into a hysterical, war-mongering pop-

ulation which wanted to destroy everything German, tear

the German limb to limb, go to war and save the world’ [1,

p. 7].

 

Chomsky [1] analyzed the mechanisms whereby propaganda may unfold its potential: filtering information (selective perception), engineering opinion, using the public relations industry and marginalizing dissident cultures.

 

In his latest essay, Chomsky [2] describes how these mechanisms are operational in the world events following the September 11 tragedy (the Afghanistan war).

 

In the past 2 decades, clinical medicine has witnessed the emergence of special interest groups [3]. Corporate interests have fused with academic medicine to create an unhealthy alliance that works against objective reporting of clinical research (selective perception), sets up meetings and symposia with the specific purpose of selling the participants to the sponsors (engineering opinions), gets its prodigal experts into leading roles in journals, medical associations and nonprofit research organizations (public relations industry) and provides the appropriate degree of rejection of outliers (marginalization of dissident cultures).

 

Current trends in prescribing antidepressant drugs provide an excellent example of the risk which clinical medicine faces.

 

Long-Term Use of Antidepressant Drugs

 

The starting point of this discussion is an issue which became very apparent in the 1990s, i.e. the high rate of relapse following discontinuation of antidepressant drugs in unipolar depression [4]. On the basis of a few controlled trials, long-term use of antidepresssant drugs to avoid relapse was advocated and became a common clinical practice [5]. This led to both extension of the duration of antidepressant drug therapy to the longest possible time for treating the acute episode of depression and suggestion of an indefinite (lifelong) pharmacological prevention of depression. At about the same time, the effectiveness of

antidepressant drugs in the short-term treatment of anxiety disorders and the chronicity of many forms of anxiety disturbances paved the way for justification of years of ongoing drug treatment [6].

 

The availability of antidepressant drugs which are far more tolerable than traditional tricyclics has also led to an extension of their use to forms of depression which do not reach the severity threshold of major depressive disorders and can be subsumed under the rubrics of minor depression and demoralization, despite lack of evidence for their efficacy in these situations [7]. Leading journal articles, symposia and practice guidelines push clinicians toward prescribing antidepressant drugs more and more. This propaganda, with respect to which the taint of conflict of interests has been highlighted recently in a consumer

magazine [8], makes the clinician who would retain a cautious and balanced attitude feel like the person whom Chomsky [1] depicts as sitting alone in front of the TV, thinking that he must be crazy or outdated for not buying what comes out of the tube.

 

Selective Perception

 

Selective attention to the pharmacological aspects of depression therapy induced by propaganda can make the clinician unaware of a number of research findings which are worthy of clinical interest. Propaganda makes sure that these issues are neglected, if not carefully avoided.

 

They are summarized in the following sections.

 

The Duration of Drug Treatment Does Not Seem to

Affect Long-Term Prognosis once the Drug is

Discontinued

 

There is evidence that casts doubt on the ability of antidepressant drugs to favorably affect the course of depressive illness, despite their recognized ability to treat the depressive episode and to prevent relapse while the patient is taking the drug. Viguera et al. [9] analyzed 27 studies with variable lengths of antidepressant treatment which reported follow-up of drug discontinuation. The duration of drug treatment did not seem to affect the long-term prognosis once the drug was discontinued.

 

Whether you treat a depressed patient for 3 months or 3 years, it

does not matter when you stop the drug (it does matter, of course, whether patients are on drugs or placebo). Indeed, there was a nonsignificant trend which suggested that the longer the drug treatment, the higher the likelihood of relapse [9].

 

An observational study of 236 patients with unipolar depression who had received antidepressants during recovery and were followed for an affective recurrence for up to 5 years showed that the rate of recurrence for patients with fewer than five previous episodes was not affected by medication after the initial 8 months [10].

 

These issues are amplified in the setting of anxiety disorders, where relapse after discontinuation of antidepressant drugs is even more common [11] and joint use of psychotherapy and antidepressants has been found to yield a worse prognosis than psychotherapy alone [12-15].

 

The Efficacy of Antidepressant Drugs Has Been

Overemphasized

 

A recent analysis of 186 randomized controlled trials comparing amitriptyline with other antidepressant drugs (including selective serotonin reuptake inhibitors; SSRIs) disclosed the clear superiority of amitriptyline in terms of recovery rates [16]. Since amitriptyline is one of the oldest antidepressants, this means that while considerable progress has been made in terms of side effects profile, little (if any) has been made in terms of efficacy. Not surprisingly, the presence of residual symptomatology upon pharmacological treatment has been substantiated in the majority of successfully treated patients [4].

 

Residual symptoms are among the most powerful predictors of relapse [4], and their abatement by means of cognitive behavioral strategies has been found to improve long-term outcome [17–19].

 

The findings on residual symptoms of successfully treated depressed patients are reinforced by the very high percentage of patients who do not respond to drug treatment (up to 50%) [20].

 

The conclusion that can be drawn is that pharmacological treatment

of depression does not provide the solution for a substantial proportion of depressive episodes and is likely to leave residual symptomatology.

 

Loss of Efficacy Occurs during Maintenance

Treatment of Depression

 

The return of depressive symptoms during maintenance antidepressant treatment – which has been found to occur in 9–57% of patients in published trials [21] – is a common, vexing problem. Relapse of depression has also been found to occur during the follow-up of patients receiving tricyclic antidepressants for panic disorder [22].

 

Some studies point to dispositional (pharmacokinetic) tolerance, which reduces the concentration of a drug or its duration of action [23]. Other studies, however, suggest the likelihood that pharmacodynamic processes change sensitivity to the drug [24]. In particular, the oppositional model of tolerance (continued drug treatment may recruit processes that oppose the initial acute effect of a drug or its receptor modifications) seems to entail a considerable explanatory power [23, 25]. In clinical terms, increasing the dosage of the antidepressant drug does not always

help, and, when it does, it may yield only temporary relief. Since this is a very touchy area for the pharmaceutical industry, there is insufficient research on these crucial clinical issues.

 

The Full Meaning of Withdrawal Reactions from

Antidepressant Drugs Is Not Appreciated

 

Withdrawal symptoms following discontinuation of antidepressants were recognized soon after the introduction of these drugs [26]. They have been described with all types of antidepressant drugs, but particularly with SSRIs [27–30]. From a randomized controlled trial [31], we know that not all SSRIs induce a ‘discontinuation’ syndrome (as the propaganda of special interest groups redefined withdrawal reactions) to the same degree; fluoxetine is less prone to do so than paroxetine or sertraline.

 

What we do not know is what all this really means. Are withdrawal phenomena simply bothersome and self-limiting reactions or are they a sign of something else? As Grahame-Smith [32] has aptly stated: ‘Chronic drug therapy may induce a sleeping tiger, which awakens when the drug therapy is stopped and results in rebound withdrawal effects with serious consequences, as with many drug addictions’ [p. 227].

 

But what is this ‘sleeping tiger’? The inverse relationship between the duration of maintenance antidepressant treatment and the time to recurrence off treatment [9] raises concern about the induction of a vicious circle. It in fact suggests the possibility of an addiction model whose most immediate clinical manifestations are withdrawal symptoms [29]. According to a sensitization hypothesis [23], antidepressant drugs may facilitate relapse once they are discontinued and worsen illness outcome.

 

The possibility that antidepressant drugs may induce acceleration of episodes has not been adequately studied in unipolar depression, but it is widely recognized in bipolar disorder [23]. Goodwin [33] has illustrated how this could occur. If both depressive and manic episodes tend naturally to evolve toward remission (either into a euthymic phase or into an episode of opposite polarity), and if antidepressant drugs accelerate this

natural tendency, drug treatment may accelerate the next sequence in the natural course (i.e. the onset of a manic episode instead of euthymia). Goodwin [33] stated it thus:

 

‘If the natural sequence of recurrent unipolar illness goes

from depression to recovery and then eventually to the

next episode, treatments that accelerate recovery of the

index depression could also accelerate the onset of the

next episode’ [p. 43].

 

These clinical phenomena (withdrawal and sensitization) may also apply to the long-term use of antidepressant drugs in anxiety disorders [11, 34].

 

Nonpharmacological Prevention Strategies Are

Neglected

 

It is ironic that while psychiatrists view prevention of relapse of depression purely in pharmacological terms as if it were a disease such as diabetes [5], diabetologists emphasize the importance of nonpharmacological strategies (lifestyle modification) in the prevention of type 2 diabetes mellitus [35].

 

This is a perfect exemplification of a phenomenon described by Lipowski [36] in the late 1980s: ‘... after a period marked by one-sided emphasis on psychodynamics and social issues, or what could be called “brainless” psychiatry on account of its relative neglect of cerebral processes, we are witnessing an opposite trend

towards extreme biologism or “mindless” psychiatry’ [p.244].

 

Yet, there is now extensive evidence for the role of cognitive behavioral psychotherapy in the prevention of relapse in unipolar depression [17–19, 37–40].

 

Ryff and Singer [41] remark that mental health research is dramatically weighted on the side of psychological dysfunction and that health is equated to the absence of illness rather than to the presence of wellness. They suggest that the absence of well-being creates conditions of vulnerability to possible future adversities and that the route to recovery does not lie exclusively in alleviating the negative, but also in engendering the positive. In depression research, little attention is paid to the balance between positive and negative affects [42] and to the promotion of psychological well-being [17]. Similarly, life-

style modification, which is widely practiced for the prevention of relapse in myocardial infarction [43], is not even considered in clinical psychiatry, despite the fact that depressed patients are often unaware of the long-term consequences of a maladaptive lifestyle which does not take chronic stress, interpersonal friction and excessive and inadequate rest into consideration [17].

 

Is This the Right Way?

 

Antidepressant drugs were developed and found to be effective in the treatment of the major depressive episode [44]. In recent years, however, their use has been prolonged and extended to maintenance and prevention, with apparently reassuring results in comparison with placebo [45]. However, treatments that are effective in the acute phase of illness are not necessarily the most suitable for postacute and residual phases or maintenance [46].

 

If we are able to remove the conceptual obstacles that obstruct our view [47] and silence the sound of propaganda, we may then become aware of a different scenario.

 

We are stretching the original indications (major depressive episodes) of drugs of modest efficacy to include prevention of relapse, anxiety disorders and demoralization. Patients do not suddenly become well, but tend to gradually lose their depressive symptoms over the months following treatment [48]. Stassen et al. [49] found that the time course of improvement among responders to amitriptyline, oxaprotiline and placebo was independent of the treatment modality and thus identical in the three groups. Once triggered, the time course of recovery from illness became identical to the spontaneous remission under placebo.

 

Antidepressant drugs, therefore, may not change the pattern of the natural course of recovery from depressive illness, but simply speed the recovery and change the boundary between ‘responders’ and ‘nonresponders’ [49]. When we prolong treatment over 6–9 months, we may thus recruit different phenomena, such as tolerance, episode acceleration, sensitization and paradoxical effects [23]. Antidepressant drugs may still be superior to placebo, but their hidden costs may far outweigh their apparent gains.

 

A series of excellent studies by a research group in Seattle is illustrative of this unfair trade. Three hundred and eighty-six patients with recurrent major depression or dysthymia who had recovered after 8 weeks of antidepressant treatment prescribed by their primary care physicians were randomized to a relapse prevention program (based on pharmacological treatment) or standard primary care [50]. There were no significant differences in episodes of relapse. However, patients in the intervention

group were significantly more likely to refill medication prescriptions over the 12-month follow-up. In another study [51], there were no substantial differences between depressive patients treated by psychiatrists and those treated by primary care physicians. A third investigation [52] disclosed significant differences between an intervention arm (based on the use of paroxetine) and a standard-care arm in panic disorder, particularly in the first 6 months.

 

We wonder, however, what would happen subsequently, if patients tried to discontinue paroxetine. Even if they were treated with an approach entailing enduring effects (cognitive behavioral therapy), their course would be less favorable than if paroxetine had not been used at all [12–15].

 

Carroll [53] anticipated the effects of inappropriate trends in the prescribing of antidepressant drugs 2 decades ago, in the following statement: ‘... we strongly suspect that many patients who are simply unhappy or dysphoric receive these drugs, with predictable consequences in terms of mortality from overdose, economic waste and irrational, unproductive clinical management’.

 

An Alternative Approach

 

In recent years, a new way of integrating pharmacotherapy and psychotherapy in depression has been proposed, i.e. the sequential approach [54]. According to this model, which has been validated in randomized controlled trials in unipolar depression [17–19, 38] and in a pilot investigation in bipolar disorder [55], pharmacotherapy is used in the acute phase of depression and cognitive behavioral psychotherapy in the residual phase. Its

preventive effects appeared to be related to the abatement of residual symptoms and/or an increase in psychological well-being and coping skills.

 

The practical steps for implementing this approach are described in table 1 and detailed elsewhere [56]. It may include discontinuation of antidepressant drug treatment, as outlined here, or its maintenance. It may offer the advantage of yielding enduring effects while limiting the exposure to drug therapy.

 

As to anxiety disorders, effective cognitive behavioral strategies have been developed which are likely to entail long-lasting effects [11–15]. These therapies challenge the routine use of antidepressant drugs, unless specific clinical situations occur, such as depression comorbidity.

 

Not surprisingly, advocates of nonpharmacological treatment strategies are swimming against the tide of pharmaceutical propaganda. Those who are involved in mental health (both as care providers and consumers), however, should be aware that life after antidepressant drugs does exist and that it may be far more gratifying for both. Psychiatrists, in particular, may rediscover the spectacular achievements of competent treatment and the joy

of intellectual freedom.

 

-----------------------------------------------------------------

Table 1. Steps for implementing the sequential approach in recur-

rent depression [56]

 

1. Careful assessment of the patient 3 months after antidepressant

drug treatment, with both observer-rated instruments (with spe-

cial reference to anxiety and irritability) and self-observation

(diary)

2 Cognitive behavioral treatment of residual symptoms (cognitive

restructuring and/or homework exposure), if present

3 Tapering of antidepressant drug treatment at the slowest possible

pace (such as 25 mg of a tricyclic every other week)

4 Well-being-enhancing therapy (well-being therapy) and lifestyle

modification

5 Discontinuation of antidepressant drugs

6 Careful assessment of the patient 1 month after drug discontinua-

tion

-----------------------------------------------------------------

 

 

Acknowledgements

 

This paper was supported in part by grants from the Mental

Health Outcome Assessment Project (Istituto Superiore di Sanità,

Rome, Italy) and Ministero dell’Università e della Ricerca Scientifica e Tecnologica (Rome, Italy).

 

References

1 Chomsky N: Media Control: The Spectacular Achievements of Propaganda. New York, Seven Stories, 1997.

2 Chomsky N: 9–11. New York, Seven Stories, 2001.

3 Fava GA: Conflict of interest and special interest groups. The making of a counter culture. Psychother Psychosom 2001;70:1–5.

4 Fava GA: Subclinical symptoms in mood disorders: Pathophysiological and therapeutic implications. Psychol Med 1999;29:47–61.

5 Andrews G: Should depression be managed as a chronic disease? BMJ 2001;322:419–421.

6 Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry 1998;155(5 suppl):1–34.

7 Meek C: Fraud and misconduct in medical research. Health Which, December 2001, pp 21–24.

8 Paykel ES, Hollyman JA, Freeling P, Sedgwick P: Predictors of therapeutic benefit from amitriptyline in mild depression: A general practice placebo-controlled trial. J Affect Disord

1988;14:83–95.

9 Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998;5:293–306.

10 Dawson R, Lavori PW, Coryell WH, Endicott J, Keller MB: Maintenance strategies for unipolar depression: An observational study of levels of treatment and recurrence. J Affect Disord 1998;49:31–44.

11 Marks IM: Behavioural and drug treatments of phobic and obsessive-compulsive disorders. Psychother Psychosom 1986;46:35–44.

12 Brown TA, Barlow DH: Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 1995;63:754–765.

13 Otto MW, Pollack MH, Sabatino SA: Maintenance of remission following cognitive behavior therapy for panic disorder. Behav Ther

1996;27:473–482.

14 Barlow DH, Gorman JM, Shear MK, Woods SW: Cognitive-behavioral therapy, imipramine, or their combination for panic disorder:

A randomized controlled trial. JAMA 2000; 283:2529–2536.

15 Fava GA, Rafanelli C, Grandi S, Conti S, Ruini

C, Mangelli L, Belluardo P: Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med 2001;31:

891–898.

16 Barbui C, Hotopf M: Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129–144.

17 Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P: Prevention of recurrent depression with cognitive behavioral therapy: Preliminary findings. Arch Gen Psychiatry 1998;55:816–

820.

18 Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA: Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998;155:

1443–1445.

19 Paykel ES, Scott J, Teasdale JD, Johnson AL, Garlan A, Moore R, Jenaway A, Cornwall PL, Hayhurst H, Abbot R, Pope M: Prevention of

relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999;56:829–835.

20 Fava M, Kendler KS: Major depressive disorder. Neuron 2000;28:335–341.

21 Byrne SE, Rothschild AJ: Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. J Clin Psychiatry 1998;59:279–288.

22 Noyes R Jr, Garvey MJ, Cook BL: Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989;16: 249–257.

23 Fava GA: Potential sensitising effects of antidepressant drugs on depression. CNS Drugs 1999;12:247–256.

24 Baldessarini RJ: Risks and implications of interrupting maintenance psychotropic drug therapy. Psychother Psychosom 1995;63:137–141.

25 Sonino N, Fava GA: CNS drugs in Cushing’s disease. Pathophysiological and therapeutic implications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry, in press.

26 Kramer JC, Klein DF, Fink M: Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961;118:549–550.

27 Oliver JS, Burrows GD, Norman TR: Discontinuation syndromes with selective serotonin reuptake inhibitors. CNS Drugs 1999;12:171–177.

28 Medawar C: The antidepressant web. Int J Risk Saf Med 1997;10:75–126.

29 Fava GA, Tomba E: The use of antidepressant drugs: Some reasons for concern. Int J Risk Saf Med 1998;11:271–275.

30 Shoenberger D: Discontinuing paroxetine: A personal account. Psychother Psychosom, in press.

31 Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized

clinical trial. Biol Psychiatry 1998;44:77–87.

32 Grahame-Smith DG: The Lilly Prize Lecture. 1996. ‘Keep on taking the tablets’: Pharmacological adaptation during long-term drug therapy. Br J Clin Pharmacol 1997;44:227–238.

33 Goodwin FK: The biology of recurrence: New directions for the pharmacologic bridge. J Clin Psychiatry 1989;50(suppl 4):40–47.

34 Ruini C, Fava GA: The broad definition of treatment hinders a clinical translation of the findings. Am J Psychiatry, in press.

35 Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A,

Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glu-

cose tolerance. Finnish Diabetes Prevention Study Group. N Engl J Med 2001;344:1343–1350.

36 Lipowski ZJ: Psychiatry: Mindless or brainless, both or neither? Can J Psychiatry 1989;34: 249–254.

37 Blackburn IM, Moore RG: Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recur-

rent depression. Br J Psychiatry 1997;171:328–334.

38 Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lan MA: Prevention of relapse/recurrence in major depression by

mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68:615–623.

39 Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC: Preventing recurrent depression using cognitive therapy with and without a continuation phase: A randomized clinical

trial. Arch Gen Psychiatry 2001;58:381–388.

40 Jarrett RB, Kraft D, Schaffer M, Witt-Browder A, Risser R, Atkins DH, Doyle J: Reducing relapse in depressed outpatients with atypical features: A pilot study. Psychother Psychosom

2000;69:232–239.

41 Ryff CD, Singer B: Psychological well-being: Meaning, measurement, and implications for psychotherapy research. Psychother Psychosom 1996;65:14–23.

42 Rafanelli C, Park SK, Ruini C, Ottolini F, Cazzaro M, Fava GA: Rating well-being and distress. Stress Med 2000;16:55–61.

43 Bankier B, Littman AB: Psychiatric disorders and coronary heart disease in women – a still neglected topic: Review of the literature from 1971 to 2000. Psychother Psychosom 2002;71:

133–140.

44 Bech P: Pharmacological treatment of depressive disorders: A review; in Maj M, Sartorius N (eds): Depressive Disorders. Chichester, Wiley, 1999, pp 89–127.

45 Kupfer DJ: Maintenance treatment in recurrent depression: Current and future directions. The first William Sargant Lecture. Br J Psychiatry 1992;161:309–316.

46 Fava GA: The concept of recovery in affective disorders. Psychother Psychosom 1996;65:2–13.

47 Fava GA: Conceptual obstacles to research progress in affective disorders. Psychother Psychosom 1997;66:283–285.

48 Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RMA, Shea T: Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospec-

tive follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809–816.

49 Stassen HH, Delini-Stula A, Angst J: Time course of improvement under antidepressant treatment: A survival-analytical approach. Eur

Neuropsychopharmacol 1993;3:127–135.

50 Katon W, Rutter C, Ludman EJ, Von Korff M, Lin E, Simon G, Bush T, Walker E, Unutzer J: A randomized trial of relapse prevention of

depression in primary care. Arch Gen Psychiatry 2001;58:241–247.

51 Simon GE, Von Korff M, Rutter CM, Peterson DA: Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry 2001;58:395–401.

52 Roy-Byrne PP, Katon W, Cowley DS, Russo J: A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch Gen Psychiatry 2001;58:869–

876.

53 Carroll BJ: Neurobiologic dimensions of depression and mania; in Angst J (ed): The Origins of Depression. Berlin, Springer, 1983, pp 163–186.

54 Fava GA: Sequential treatment: A new way of integrating pharmacotherapy and psychotherapy. Psychother Psychosom 1999;68:227–229.

55 Fava GA, Bartolucci G, Rafanelli C, Mangelli L: Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. J Clin Psychiatry 2001;

62:556–559.

56 Fava GA, Ruini C: Psychotherapy of residual symptoms; in Alpert J, Fava M (eds): Handbook of Chronic Depression. New York, Dek-

ker, in press.

 

full text at http://www.mediafire.com/file/4xd79ph5iw1z2l9/02_LT%20treatment%20propaganda_fava.pdf

Edited November 20, 2012 by Altostrata
added Pubmed citation

[Altostrata]

Am J Psychiatry. 1998 Oct;155(10):1443-5.

 

Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression.

 

Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA.

 

Source

Department of Psychiatry, State University of New York at Buffalo, VA Medical Center, USA.

 

Abstract and free full text at http://www.ncbi.nlm.nih.gov/pubmed/9766780

 

OBJECTIVE:

 

The authors' goal was to determine whether cognitive behavioral treatment of residual symptoms of depression might have a significant effect on relapse rate.

 

METHOD:

 

A 6-year follow-up assessment was conducted of 40 patients with primary major depressive disorder who had been successfully treated with antidepressants and were randomly assigned to either cognitive behavioral treatment of residual symptoms or standard clinical management.

 

RESULTS:

 

Ten of the patients (50%) in the cognitive behavioral treatment group and 15 (75%) in the standard clinical management group relapsed. The difference did not attain statistical significance. When multiple relapses were considered, patients in the cognitive behavioral treatment group had a significantly lower number of depressive episodes than those in the standard clinical management group. Patients responded to the same antidepressant drug used in the index episode; in two cases (4%), resistance occurred.

 

CONCLUSIONS:

 

The protective effects of cognitive behavioral treatment that were evident at 4-year follow-up faded afterward. Cognitive behavioral treatment of residual symptoms, however, improved the long-term outcome of major depression in terms of total number of episodes during the follow-up period.

[Altostrata]

BMJ. 2001 Jun 9;322(7299):1428.

Patients with depression can be taught how to improve recovery.

 

Fava GA, Ruini C, Mangelli L.

 

free full text at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1120485/

 

Editor—Andrews has emphasised the chronic nature of depression and the need for endorsing treatment protocols such as those used for diabetes.1 He has also raised the issue of being more honest with people about their prognosis and the need for prolonged treatment, particularly pharmacotherapy. But duration of treatment does not seem to affect long term prognosis once the drug is stopped.2

 

Whether you treat a depressed patient for three months or three years, it does not matter when you stop the drug. Indeed, a non-significant trend suggests that the longer the drug treatment is, the higher the likelihood of relapse.2 Despite treating depression effectively in the short term, antidepressant drugs may worsen its course through a sensitisation process.3 Several clinical findings point to this possibility: paradoxical (depression-inducing) effects of switching antidepressants and cycle acceleration in bipolar disorder; tolerance to the effects of antidepressants during long term treatment; the onset of resistance on rechallenge with the same antidepressant in some patients; and withdrawal syndromes after drugs that elevate mood are stopped.3

 

The pharmaceutical industry may not like this hypothesis, but a promising alternative exists. Treatment of depression by pharmacological means is likely to leave residual symptoms in most patients.4 Such symptoms hinder lasting recovery and are one of the strongest risk factors for relapse. In two randomised controlled studies cognitive behavioural treatment of residual symptoms significantly improved long term outcome of recurrent depression.4,5 In our affective disorders programme we tell our depressed patients that depression is likely to recur. But we also teach them that if they can change their lifestyle (with its maladaptive consequences), decrease their residual symptoms (particularly anxiety and irritability), and improve their psychological wellbeing the chances of a lasting recovery are far better.4

 

Rather than look to diabetologists, psychiatrists should be more inclined to look to cardiologists when they encourage their patients to reduce their risk factors (including type A behaviour) after a myocardial infarction. In our experience, patients in remission generally like the open and challenging nature of this type of communication. If people have a right to the truth, as Andrews says, they are entitled to the full story.

 

References

 

Andrews G. Should depression be managed as a chronic disease? BMJ 2001;322:419-21. (17 February.)

 

Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harvard Rev Psychiatry 1998;5:293-306.

 

Fava GA. Potential sensitising effects of antidepressant drugs on depression. CNS Drugs 1999;12:247-56.

 

Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy. Arch Gen Psychiatry 1998;55:816-20.

 

Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999;56:829-35.

[Altostrata]

Does the use of antidepressants induce chronicity in depression? Robert Whitaker discusses this issue, based on Dr. Fava's work, on his blog Mad in America: http://www.madinamerica.com/madinamerica.com/Whitaker/EBC6876C-A2FA-41F8-A090-366868D09A8F.html and in his book, Anatomy of an Epidemic.

 

(We believe that much of this hypothesized chronicity is prolonged withdrawal syndrome misidentified as relapse of depression. As prolonged withdrawal syndrome has never been followed more than a year, and appears to resolve over time, we believe recovery is possible.)

 

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 20. [Epub ahead of print]

 

The mechanisms of tolerance in antidepressant action.

 

Fava GA, Offidani E.

 

Source

Affective Disorders Program, Department of Psychology, University of Bologna, Bologna, Italy; Department of Psychiatry, State University of New York at Buffalo, Buffalo, New York, USA.

 

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/20728491 Full text at http://www.mediafire.com/?hy2rc7psouzewx6

 

There is increasing awareness that, in some cases, long-term use of antidepressant drugs (AD) may enhance the biochemical vulnerability to depression and worsen its long-term outcome and symptomatic expression, decreasing both the likelihood of subsequent response to pharmacological treatment and the duration of symptom-free periods. A review of literature suggesting potential side effects during long treatment with antidepressant drugs was performed. Studies were identified electronically using the following databases: Medline, Cinahl, PsychInfo, Web of Science and the Cochrane Library. Each database was searched from its inception date to April 2010 using "tolerance", "withdrawal", "sensitization", "antidepressants" and "switching" as key words. Further, a manual search of the psychiatric literature has been performed looking for articles pointing to paradoxical effects of antidepressant medications. Clinical evidence has been found indicating that even though antidepressant drugs are effective in treating depressive episodes, they are less efficacious in recurrent depression and in preventing relapse. In some cases, antidepressants have been described inducing adverse events such as withdrawal symptoms at discontinuation, onset of tolerance and resistance phenomena and switch and cycle acceleration in bipolar patients. Unfavorable long-term outcomes and paradoxical effects (depression inducing and symptomatic worsening) have also been reported. All these phenomena may be explained on the basis of the oppositional model of tolerance. Continued drug treatment may recruit processes that oppose the initial acute effect of a drug. When drug treatment ends, these processes may operate unopposed, at least for some time and increase vulnerability to relapse. Antidepressant drugs are crucial in the treatment of major depressive episodes. However, appraisal and testing of the oppositional model of tolerance may yield important insights as to long-term treatment and achievement of enduring effects.

[Altostrata]

Here are more of Dr. Fava's papers questioning whether antidepressants do more harm than good. Full text for all the following at http://www.madinamerica.com/madinamerica.com/Depression.html

 

The descriptions below are Robert Whitaker's.

 

Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Fava, G. Psychotherapy and Psychosomatics 61 (1994):125-31.

 

“The time has come for debating and initiating research into the likelihood that psychotropic drugs actually worsen, at least in some cases, the progression of the illness which they are supposed to treat,” writes Fava.

 

Can long-term treatment with antidepressant drugs worsen the course of depression? Fava, G. Journal of Clinical Psychiatry 64 (2003):123-33.

 

The brain compensates to adapt to the disruption of neurotransmitter activity while on the antidepressant medication; “when drug treatment ends, these (compensatory) process may operate unopposed, resulting in appearance of withdrawal symptoms and increased vulnerability to relapse,” Fava said.

Holding on, depression, sensitization by antidepressant drugs, and the prodigal experts. Fava, G. Psychotherapy and Psychosomatics 64 (1995):57-61.

 

Antidepressant drugs may worsen the progression of the disease in the long term, by increasing the patient’s biochemical vulnerability to depression.

 

Potential sensitising effects of antidepressant drugs on depression. Fava, G. CNS Drugs 12 (1999): 247-56.

 

Antidepressants may cause a more treatment-resistant form of depression.

[Altostrata]

CNS Drugs 1999;12:247-56.

Potential sensitising effects of antidepressant drugs on depression.

 

Fava GA.

 

Abstract at http://www.ingentaconnect.com/content/adis/cns/1999/00000012/00000004/art00001 Full text at http://www.madinamerica.com/madinamerica.com/Depression.html

 

The possibility that antidepressant drugs, while effectively treating depression in the short term, may worsen its course through a sensitisation process has been proposed. Although this hypothesis has not been extensively tested, a number of clinical findings point toward this possibility: the very unfavourable long term outcome of major depression when treated by pharmacological means; paradoxical (depression-inducing) effects of antidepressant drugs in some patients with mood and anxiety disturbances; antidepressant-induced switching and cycle acceleration in bipolar disorder; the occurrence of tolerance to the effects of antidepressants during long term treatment; the onset of resistance upon rechallenge with the same antidepressant drug in some patients; and withdrawal syndromes following discontinuation of mood-elevating drugs.

 

The occurrence of a process of sensitisation in susceptible individuals may be explained on the basis of the oppositional model of tolerance. Continued drug treatment may recruit processes that oppose the initial acute effects of a drug. When drug treatment ends, these processes may operate unopposed, at least for some time. This hypothesis is, however, substantially untested and its scientific exploration is likely to encounter considerable methodological and ideological difficulties. It needs to be verified by epidemiological studies, controlled clinical trials, follow-up studies and psychobiological investigations.

 

The clinical implications of the sensitisation hypothesis in depression are considerable. The treatment of depression with antidepressant drugs would not be questioned, but its modalities and applications may undergo important changes. A number of current practices would need to be re-examined such as the (inappropriate) use of antidepressant drugs in minor mood disturbances, the treatment of anxiety disorders with antidepressants, the use of suboptimal dosages of antidepressant drugs, the application of antidepressants as prophylactic agents, and modalities of discontinuation. A cost-benefit appraisal of psychotherapeutic versus pharmacological treatment would also need to be considered.

 

Even though the hypothesis of sensitising effects of antidepressant drugs, at present, has no empirical support, it is important enough to deserve extensive studies and debate.

[Altostrata]

J Clin Psychiatry. 2003 Feb;64(2):123-33.

 

Can long-term treatment with antidepressant drugs worsen the course of depression?

 

Fava GA.

 

Source

Department of Psychiatry, State University of New York at Buffalo, USA.

 

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/12633120 Full text at http://www.madinamerica.com/madinamerica.com/Depression.html

 

Background: The possibility that antidepressant drugs, while effectively treating depression, may worsen its course has received inadequate attention.

 

Method: A review of the literature suggesting potential depressogenic effects of long-term treatment with antidepressant drugs was performed. A MEDLINE search was conducted using the keywords tolerance, sensitization, antidepressive agents, and switching. This was supplemented by a manual search of Index Medicus under the heading "antidepressant agents" and a manual search of the literature for articles pointing to paradoxical effects of antidepressants.

 

Results: A number of reported clinical findings point to the following possibilities: very unfavorable long-term outcome of major depression treated by pharmacologic means, paradoxical (depression-inducing) effects of antidepressant drugs in some patients with mood and anxiety disturbances, antidepressant-induced switching and cycle acceleration in bipolar disorder, occurrence of tolerance to the effects of antidepressants during long-term treatment, onset of resistance upon rechallenge with the same antidepressant drug in a few patients, and withdrawal syndromes following discontinuation of mood-elevating drugs. These phenomena in susceptible individuals may be explained on the basis of the oppositional model of tolerance. Continued drug treatment may recruit processes that oppose the initial acute effects of a drug and may result in loss of clinical effect. When drug treatment ends, these processes may operate unopposed, at least for some time, and increase vulnerability to relapse.

 

Conclusion: The possibility that antidepressant drugs may worsen the course of depression needs to be tested, even though its scientific exploration is likely to encounter considerable methodological and ideological difficulties. The clinical implications of this hypothesis in depression are considerable. Antidepressant drugs are crucial in the treatment of major depressive episodes. However, appraisal of paradoxical effects that may occur in susceptible patients during long-term treatment may lead to more effective use of the drugs.

[Altostrata]

Psychother Psychosom. 2007;76(5):260-5.

The road to recovery from depression--don't drive today with yesterday's map.

 

Fava GA, Tomba E, Grandi S.

 

Affective Disorders Program and Laboratory of Experimental Psychotherapy, Department of Psychology, University of Bologna, Italy. giovanniandrea.fava@unibo.it

 

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/17700045 Full text at http://www.mediafire.com/?w1v2k62pws3jiha

 

The issue of recovery is getting increasing attention in depression research, particularly after the publication of the STAR*D results. The paper analyzes some issues which may hinder effective treatment of major depressive disorders: the inadequacies of a cross-sectional DSM assessment without clinical differentiation of the extent, development and seriousness of the disturbances (staging); over-emphasis on and prolongation of drug treatment, without paying attention to problems related to tolerance; neglect of the active role of the patient in achieving recovery, with the integration of psychotherapeutic strategies in a sequential model. If we are able to remove the conceptual obstacles which obstruct our view of depression and silence the sound of propaganda, we may then become aware of a different scenario in mood disorders and be able to develop therapeutic strategies of enduring quality.

[Altostrata]

Psychol Med. 2007 Mar;37(3):307-17.

 

The concept of recovery in major depression.

Fava GA, Ruini C, Belaise C.

 

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/17311684 Full text requested.

 

BACKGROUND:

 

There is increasing literature on the unsatisfactory degree of remission that current therapeutic strategies yield in unipolar depression. The aims of this review were to survey the available literature on residual symptoms of depression, to introduce new targets for therapy and to outline a more stringent definition of recovery.

 

METHOD:

 

Studies were identified by using MEDLINE (English language articles published from 1967 to June 2006; keywords: recovery, remission, residual symptoms, sequential treatment, drugs and psychotherapy, related to depressive disorder and depression) and a manual search of the literature and Index Medicus for the years 1960-2006.

 

RESULTS:

 

Most patients report residual symptoms despite apparently successful treatment. Residual symptoms upon remission have a strong prognostic value. There appears to be a relationship between residual and prodromal symptomatology. The concept of recovery should involve psychological well-being.

 

CONCLUSIONS:

 

Appraisal of subclinical symptomatology in depression has important implications for pathophysiological models of disease and relapse prevention. New therapeutic strategies for improving the level of remission, such as treatment on residual symptoms that progress to become prodromes of relapse, may yield more lasting benefits.

[Altostrata]

Psychother Psychosom. 2009;78(4):220-7. Epub 2009 Apr 28.

 

The decline of pharmaceutical psychiatry and the increasing role of psychological medicine.

Fava GA.

 

Source

 

Affective Disorders Program, Department of Psychology, University of Bologna, Bologna, Italy. giovanniandrea.fava@unibo.it

 

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/19401622 Full text at http://www.mediafire.com/?228qzcm34p15p8m

 

The increasing influence of the pharmaceutical industry on psychiatric research and practice is leading to an intellectual and clinical crisis. A narrow concept of science attempts to apply oversimplified neurobiological models to the understanding and treatment of mental disorders, and relegates psychiatrists to a marginal role. This paper reviews some emerging trends of renewal that may be subsumed under the rubric of psychological medicine: use of a multidisciplinary approach, emphasis on psychotherapeutic strategies leading to self-management, reliance on repeated assessments, integration of different treatment modalities and independence from the pharmaceutical industry. The concept of psychological medicine, defined as the clinical application of the psychosomatic approach, may provide room for innovative paths in psychiatric research and treatment.

[Shep]

Dr. Giovanni Fava and his colleagues are working to educate psychologists and therapists, in addition to psychiatrists. I've been going through some of their recent works and posting them here in the Journals section:

 

Tomba, 2017 What psychologists need to know about psychotropic medications (only the abstract is available for free, but your psychologist may be able to get the full paper with his or her professional access for research). 

 

Fava, 2017 The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders

 

Since these articles are geared toward psychologists, they have less medical jargon. For those going to a psychologist or therapist, these might be good resources to print out and give to your psychologist or therapist to help these "professionals" understand what they're dealing with. 

Edited June 28, 2019 by Shep
added information